Lupta Alinei Pușcău cu boala gravă continuă! Ce presupune

Alina Pușcău is undergoing treatment for metastatic breast cancer in the U.S., linked to the DESTINY-Breast09 clinical trial, which has shown promising results for HER2-positive patients. The trial evaluated a combination therapy of trastuzumab deruxtecan and pertuzumab, demonstrating significant improvements in disease progression and response rates. The FDA has approved this combination for first-line treatment, with positive opinions from European authorities as well. Pușcău openly shares her journey, aiming to remain optimistic despite her challenges.